UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3278-3285

2011

Volltextzugriff (PDF)

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2010-09, Vol.28 (27), p.4247-4254

2010

Volltextzugriff (PDF)

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1066-1074

2016

Volltextzugriff (PDF)

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3396-3401

2012

Volltextzugriff (PDF)

Phase II study of PX-866 in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-09, Vol.17 (9), p.1270-1274

2015

Volltextzugriff (PDF)

Primary care providers' experiences with and perceptions of personalized genomic medicine

Canadian family physician, 2016-10, Vol.62 (10), p.e626-e635

2016

Volltextzugriff (PDF)

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer

Gynecologic oncology, 2014-11, Vol.135 (2), p.184-189

2014

Volltextzugriff (PDF)

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4699-4707

2006

Volltextzugriff (PDF)

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184

Gynecologic oncology, 2010-02, Vol.116 (2), p.163-167

2010

Volltextzugriff (PDF)

Religious Values and Biobanking Decisions: An Integrative Review

Research and theory for nursing practice, 2016-01, Vol.30 (2), p.104

2016

Volltextzugriff (PDF)

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

Cancer, 2014-02, Vol.120 (4), p.603-610

2014

Volltextzugriff (PDF)

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4319-4325

2008

Volltextzugriff (PDF)

Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2178-2183

2007

Volltextzugriff (PDF)

phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

Cancer chemotherapy and pharmacology, 2010-01, Vol.65 (2), p.353-361

2010

Volltextzugriff (PDF)

Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2007-04, Vol.25 (12), p.1570-1575

2007

Volltextzugriff (PDF)

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

Investigational new drugs, 2007-10, Vol.25 (5), p.471-477

2007

Volltextzugriff (PDF)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Breast cancer research : BCR, 2017-05, Vol.19 (1), p.54-8, Article 54

2017

Volltextzugriff (PDF)

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

European journal of cancer (1990), 2008-01, Vol.44 (1), p.19-24

2008

Volltextzugriff (PDF)

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Leukemia & lymphoma, 2013-04, Vol.54 (4), p.760-766

2013

Volltextzugriff (PDF)

Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG)

European journal of cancer (1990), 2010-05, Vol.46 (8), p.1365-1373

2010

Volltextzugriff (PDF)

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

Clinical cancer research, 2009-01, Vol.15 (2), p.708-713

2009

Volltextzugriff (PDF)

Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer

Gynecologic oncology, 2013-11, Vol.131 (2), p.315-320

2013

Volltextzugriff (PDF)

Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17

European journal of cancer (1990), 2016-05, Vol.58, p.97-103

2016

Volltextzugriff (PDF)

Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1740-1745

2003

Volltextzugriff (PDF)

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

Investigational new drugs, 2008-06, Vol.26 (3), p.249-255

2008

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(74)
Middle Aged
(74)
Female
(69)
Life Sciences & Biomedicine
(68)
Science & Technology
(68)
Adult
(59)
Oncology
(59)
Male
(49)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Aged, 80 And Over
(29)
Treatment Outcome
(29)
Chemotherapy
(26)
Antineoplastic Agents - Therapeutic Use
(22)
Antineoplastic Agents
(20)
Pharmacology & Pharmacy
(20)
Pharmacology. Drug Treatments
(20)
Tumors
(20)
Drug Administration Schedule
(19)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Phase II study of PX-866 in recurrent glioblastoma

Primary care providers' experiences with and perceptions of personalized genomic medicine

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184

Religious Values and Biobanking Decisions: An Integrative Review

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG)

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer

Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17

Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

Aktive Filter

Suchergebnisse filtern